Молодежный инновационный вестник

2415-7805

Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации

11501

Conference Proceedings

Polymorphism of genes of drug metabolism enzymes in the Russian population of the Voronezh region

Khvorova

Angelina Alexandrovna

Studentgelya.xvorova@mail.ruhttps://orcid.org/0009-0000-6417-1798Goncharova

Natalia Yurievna

Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology, Voronezh State Medical University named after N.N. Burdenkosumerki_@mail.ruhttps://orcid.org/0000-0002-4113-5206Dubrovsky

Alexey Alexandrovich

Clinical pharmacologist, Head of the Department of Drug Supply, Informatization and Labor Protection of the Ministry of Health of the Republic of Crimeaoni.nekokf@gmail.comhttps://orcid.org/0009-0003-0171-5294Batishcheva

Galina Alexandrovna

Doctor of Medical Sciences, Professor, Head of the Department of Clinical Pharmacology, Voronezh State Medical University named after N.N. Burdenko, Ministry of Health of the Russian Federationbat13@mail.ruhttps://orcid.org/0000-0003-4771-7466

Burdenko Voronezh State Medical University

01102026

15S1212213

09032026

05042026

2026

Individual genetic characteristics of the patient play a key role in the effectiveness and safety of pharmacotherapy. The most studied methods in this aspect are pharmacogenetics, which make it possible to predict the body's response to drugs based on the analysis of genes encoding carrier proteins, receptors, and metabolic enzymes. Studies show that the prevalence of polymorphic markers varies significantly among representatives of different ethnic groups. This work is devoted to the analysis of pharmacokinetic markers of the CYP2C19, CYP2C9 (cytochrome P450 system) genes and the MDR1 gene encoding p-glycoprotein in the population of the Voronezh region. The choice of these markers is due to their key role in drug metabolism. The frequency of carriage of polymorphic variants of these genes among the population of the region has been determined. The data obtained make it possible to predict with high probability the characteristics of the response to drug therapy in patients of the Voronezh region and reduce the risk of possible adverse drug reactions.

pharmacogeneticsp-glycoproteincytochrome P450clopidogrelwarfarinoral anticoagulants

фармакогенетикар-гликопротеинцитохром Р450клопидогрелварфариноральные антикоагулянты

Li Y, Yuan H, Yang K, et al. The structure and function of P-glycoprotein. Curr Med Chem 2010;17(8):786-800.

Lee CY, Lai TY, Wu YM, et al. Gene Expression of P-glycoprotein and Cytochrome P450 3A4 in Peripheral Blood Mononuclear Cells and Correlation With Expression in Liver. //Transplant Proc 2010;42(3):834-6

Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции // Рациональная Фармакотерапия в Кардиологии 2019;15(3):393-406.

Сычев Д.А., Сычев И.Н., Мирзаев К.Б., Рыткин Э.И., Иващенко Д.В., Буре И.В., Отделенов В.А. Клинико- фармакологические технологии персонализации фармакотерапии сердечно-сосудистых заболеваний: фокус на прямые оральные антикоагулянты. //Вестник РАМН. 2019;74(5):299–306.

Прикладная фармакогенетика: монография / под ред. Д. А. Сычева. М. Тверь: Издательство «Триада», 2021.- 496 с.